SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-092857
Filing Date
2024-08-07
Accepted
2024-08-07 16:28:12
Documents
55
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q janx-20240630.htm   iXBRL 10-Q 2339330
2 EX-10.1 janx-ex10_1.htm EX-10.1 620682
3 EX-10.2 janx-ex10_2.htm EX-10.2 31807
4 EX-31.1 janx-ex31_1.htm EX-31.1 16558
5 EX-31.2 janx-ex31_2.htm EX-31.2 15675
6 EX-32.1 janx-ex32_1.htm EX-32.1 13144
  Complete submission text file 0000950170-24-092857.txt   10486968

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT janx-20240630.xsd EX-101.SCH 1029763
57 EXTRACTED XBRL INSTANCE DOCUMENT janx-20240630_htm.xml XML 2169546
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

IRS No.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40475 | Film No.: 241184248
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)